Market Currents
Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major...
-
Thursday, January 31, 7:03 AM ETVanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major depressive disorder). VNDA says it will continue to pursue tasimelteon as a treatment for blind people with Non-24-Hour Disorder. (PR)
Other date
Latest Articles
